Preparation of a pH-responsive chitosan-montmorillonite-nitrogen-doped carbon quantum dots nanocarrier for attenuating doxorubicin limitations in cancer therapy
IF 3.9 4区 生物学Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
{"title":"Preparation of a pH-responsive chitosan-montmorillonite-nitrogen-doped carbon quantum dots nanocarrier for attenuating doxorubicin limitations in cancer therapy","authors":"Erfan Rahmani, Mehrab Pourmadadi, Sohrab Ali Ghorbanian, Fatemeh Yazdian, Hamid Rashedi, Mona Navaee","doi":"10.1002/elsc.202200016","DOIUrl":null,"url":null,"abstract":"<p>Despite its widespread usage as a chemotherapy drug in cancer treatment, doxorubicin (DOX) has limitations such as short in vivo circulation time, low solubility, and poor permeability. In this regard, a pH-responsive chitosan (CS)- montmorillonite (MMT)- nitrogen-doped carbon quantum dots (NCQDs) nanocomposite was first developed, loaded with DOX, and then incorporated into a double emulsion to further develop the sustained release. The incorporated NCQDs into the CS-MMT hydrogel exhibited enhanced loading and entrapment efficiencies. The presence of NCQDs nanoparticles in the CS-MMT hydrogel also resulted in an extended pH-responsive release of DOX over a period of 96 h compared to that of CS-MMT-DOX nanocarriers at pH 5.4. Based on the Korsmeyer-Peppas model, there was a controlled DOX release at pH 5.4, while no diffusion was observed at pH 7.4, indicating fewer side effects. MTT assay showed that the cytotoxicity of DOX-loaded CS-MMT-NCQDs hydrogel nanocomposite was significantly higher than those of free DOX (<i>p</i> < 0.001) and CS-MMT-NCQDs (<i>p</i> < 0.001) on MCF-7 cells. Flow cytometry results demonstrated that a higher apoptosis induction achieved after incorporating NCQDs nanoparticles into CS-MMT-DOX nanocarrier. These findings suggest that the DOX-loaded nanocomposite is a promising candidate for the targeted treatment of cancer cells.</p>","PeriodicalId":11678,"journal":{"name":"Engineering in Life Sciences","volume":"22 10","pages":"634-649"},"PeriodicalIF":3.9000,"publicationDate":"2022-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550734/pdf/","citationCount":"46","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Engineering in Life Sciences","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/elsc.202200016","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 46
Abstract
Despite its widespread usage as a chemotherapy drug in cancer treatment, doxorubicin (DOX) has limitations such as short in vivo circulation time, low solubility, and poor permeability. In this regard, a pH-responsive chitosan (CS)- montmorillonite (MMT)- nitrogen-doped carbon quantum dots (NCQDs) nanocomposite was first developed, loaded with DOX, and then incorporated into a double emulsion to further develop the sustained release. The incorporated NCQDs into the CS-MMT hydrogel exhibited enhanced loading and entrapment efficiencies. The presence of NCQDs nanoparticles in the CS-MMT hydrogel also resulted in an extended pH-responsive release of DOX over a period of 96 h compared to that of CS-MMT-DOX nanocarriers at pH 5.4. Based on the Korsmeyer-Peppas model, there was a controlled DOX release at pH 5.4, while no diffusion was observed at pH 7.4, indicating fewer side effects. MTT assay showed that the cytotoxicity of DOX-loaded CS-MMT-NCQDs hydrogel nanocomposite was significantly higher than those of free DOX (p < 0.001) and CS-MMT-NCQDs (p < 0.001) on MCF-7 cells. Flow cytometry results demonstrated that a higher apoptosis induction achieved after incorporating NCQDs nanoparticles into CS-MMT-DOX nanocarrier. These findings suggest that the DOX-loaded nanocomposite is a promising candidate for the targeted treatment of cancer cells.
期刊介绍:
Engineering in Life Sciences (ELS) focuses on engineering principles and innovations in life sciences and biotechnology. Life sciences and biotechnology covered in ELS encompass the use of biomolecules (e.g. proteins/enzymes), cells (microbial, plant and mammalian origins) and biomaterials for biosynthesis, biotransformation, cell-based treatment and bio-based solutions in industrial and pharmaceutical biotechnologies as well as in biomedicine. ELS especially aims to promote interdisciplinary collaborations among biologists, biotechnologists and engineers for quantitative understanding and holistic engineering (design-built-test) of biological parts and processes in the different application areas.